Lubiprostone for constipation and irritable bowel syndrome with constipation

Ashok K. Tuteja, Satish Sanku Chander Rao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic constipation and irritable bowel syndrome are heterogeneous disorders characterized by altered bowel habits, abdominal discomfort and/or difficult defecation. These conditions have a significant impact on patients' quality of life, as well as on the US economy, both in terms of healthcare costs and lost productivity. Treatment typically begins with lifestyle changes, increased fiber intake and osmotic and stimulant laxative intake. However, treatments for constipation vary in terms of their efficacy and safety. Furthermore, surveys of physicians and patients have revealed a strong desire for improved therapeutic options. Lubiprostone is a synthetic bicyclic fatty acid that is gut selective and stimulates type 2 chloride channels, resulting in increased chloride, sodium and water secretion into the lumen. The increased fluid secretion causes luminal distension, secondary peristalsis and laxation. Randomized Phase III trials have shown that lubiprostone is efficacious in the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. The US FDA has approved lubiprostone at a dose of 24 μg twice daily for the treatment of chronic idiopathic constipation in adults, and at a dose of 8 μg twice daily for irritable bowel syndrome with constipation in adult women. Nausea, diarrhea and headaches are the most commonly reported side effects. In long-term studies, lubiprostone appears to be safe.

Original languageEnglish (US)
Pages (from-to)727-733
Number of pages7
JournalExpert Review of Gastroenterology and Hepatology
Volume2
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Irritable Bowel Syndrome
Constipation
Therapeutics
Fluids and Secretions
Peristalsis
Laxatives
Chloride Channels
Defecation
Sodium Chloride
Health Care Costs
Nausea
Habits
Headache
Lubiprostone
Life Style
Diarrhea
Fatty Acids
Quality of Life
Physicians
Safety

Keywords

  • Chloride channels
  • Constipation
  • Irritable bowel syndrome
  • Lubiprostone

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Lubiprostone for constipation and irritable bowel syndrome with constipation. / Tuteja, Ashok K.; Rao, Satish Sanku Chander.

In: Expert Review of Gastroenterology and Hepatology, Vol. 2, No. 6, 01.12.2008, p. 727-733.

Research output: Contribution to journalArticle

@article{f4c9102367d042ff839d46861dba3402,
title = "Lubiprostone for constipation and irritable bowel syndrome with constipation",
abstract = "Chronic constipation and irritable bowel syndrome are heterogeneous disorders characterized by altered bowel habits, abdominal discomfort and/or difficult defecation. These conditions have a significant impact on patients' quality of life, as well as on the US economy, both in terms of healthcare costs and lost productivity. Treatment typically begins with lifestyle changes, increased fiber intake and osmotic and stimulant laxative intake. However, treatments for constipation vary in terms of their efficacy and safety. Furthermore, surveys of physicians and patients have revealed a strong desire for improved therapeutic options. Lubiprostone is a synthetic bicyclic fatty acid that is gut selective and stimulates type 2 chloride channels, resulting in increased chloride, sodium and water secretion into the lumen. The increased fluid secretion causes luminal distension, secondary peristalsis and laxation. Randomized Phase III trials have shown that lubiprostone is efficacious in the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. The US FDA has approved lubiprostone at a dose of 24 μg twice daily for the treatment of chronic idiopathic constipation in adults, and at a dose of 8 μg twice daily for irritable bowel syndrome with constipation in adult women. Nausea, diarrhea and headaches are the most commonly reported side effects. In long-term studies, lubiprostone appears to be safe.",
keywords = "Chloride channels, Constipation, Irritable bowel syndrome, Lubiprostone",
author = "Tuteja, {Ashok K.} and Rao, {Satish Sanku Chander}",
year = "2008",
month = "12",
day = "1",
doi = "10.1586/17474124.2.6.727",
language = "English (US)",
volume = "2",
pages = "727--733",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Lubiprostone for constipation and irritable bowel syndrome with constipation

AU - Tuteja, Ashok K.

AU - Rao, Satish Sanku Chander

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Chronic constipation and irritable bowel syndrome are heterogeneous disorders characterized by altered bowel habits, abdominal discomfort and/or difficult defecation. These conditions have a significant impact on patients' quality of life, as well as on the US economy, both in terms of healthcare costs and lost productivity. Treatment typically begins with lifestyle changes, increased fiber intake and osmotic and stimulant laxative intake. However, treatments for constipation vary in terms of their efficacy and safety. Furthermore, surveys of physicians and patients have revealed a strong desire for improved therapeutic options. Lubiprostone is a synthetic bicyclic fatty acid that is gut selective and stimulates type 2 chloride channels, resulting in increased chloride, sodium and water secretion into the lumen. The increased fluid secretion causes luminal distension, secondary peristalsis and laxation. Randomized Phase III trials have shown that lubiprostone is efficacious in the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. The US FDA has approved lubiprostone at a dose of 24 μg twice daily for the treatment of chronic idiopathic constipation in adults, and at a dose of 8 μg twice daily for irritable bowel syndrome with constipation in adult women. Nausea, diarrhea and headaches are the most commonly reported side effects. In long-term studies, lubiprostone appears to be safe.

AB - Chronic constipation and irritable bowel syndrome are heterogeneous disorders characterized by altered bowel habits, abdominal discomfort and/or difficult defecation. These conditions have a significant impact on patients' quality of life, as well as on the US economy, both in terms of healthcare costs and lost productivity. Treatment typically begins with lifestyle changes, increased fiber intake and osmotic and stimulant laxative intake. However, treatments for constipation vary in terms of their efficacy and safety. Furthermore, surveys of physicians and patients have revealed a strong desire for improved therapeutic options. Lubiprostone is a synthetic bicyclic fatty acid that is gut selective and stimulates type 2 chloride channels, resulting in increased chloride, sodium and water secretion into the lumen. The increased fluid secretion causes luminal distension, secondary peristalsis and laxation. Randomized Phase III trials have shown that lubiprostone is efficacious in the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. The US FDA has approved lubiprostone at a dose of 24 μg twice daily for the treatment of chronic idiopathic constipation in adults, and at a dose of 8 μg twice daily for irritable bowel syndrome with constipation in adult women. Nausea, diarrhea and headaches are the most commonly reported side effects. In long-term studies, lubiprostone appears to be safe.

KW - Chloride channels

KW - Constipation

KW - Irritable bowel syndrome

KW - Lubiprostone

UR - http://www.scopus.com/inward/record.url?scp=61549122055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549122055&partnerID=8YFLogxK

U2 - 10.1586/17474124.2.6.727

DO - 10.1586/17474124.2.6.727

M3 - Article

VL - 2

SP - 727

EP - 733

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 6

ER -